Duo Oncology
Clinical-stage biotechnology company developing ultrasmall, tumor-activated nanomedicines that co-deliver combination chemotherapies to penetrate stroma-rich solid tumors. The company’s patent-pending self‑assembling polymer chemistry is being advanced through IND-enabling studies, GLP toxicology, regulatory interactions (pre-IND, orphan designations), and planned early-phase clinical trials. Development is supported by academic licensing, NCI programs, seed financing, and NIH grants.
Industries
Nr. of Employees
small (1-50)
Duo Oncology
Pittsburgh, Pennsylvania, United States
Products
DUO-207
Lead ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel in a single intravenous formulation; advanced through GLP toxicology and IND-enabling studies with orphan designations and planned Phase I trials.
DUO-307
Ultrasmall chemo-immunotherapy nanomedicine combining a polymer-conjugated gemcitabine prodrug with a CCR2 antagonist to deliver cytotoxic and immune‑modulating agents to tumor tissue.
DUO-209
Azacytidine prodrug nanomedicine investigated for enhanced tumor targeting via in situ formation of a protein corona and immune-mediated mechanisms.
DUO-207
Lead ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel in a single intravenous formulation; advanced through GLP toxicology and IND-enabling studies with orphan designations and planned Phase I trials.
DUO-307
Ultrasmall chemo-immunotherapy nanomedicine combining a polymer-conjugated gemcitabine prodrug with a CCR2 antagonist to deliver cytotoxic and immune‑modulating agents to tumor tissue.
DUO-209
Azacytidine prodrug nanomedicine investigated for enhanced tumor targeting via in situ formation of a protein corona and immune-mediated mechanisms.
Expertise Areas
- Nanomedicine development
- Prodrug and polymer–drug conjugate chemistry
- Tumor-penetrating drug delivery
- Preclinical GLP toxicology and IND-enabling studies
Key Technologies
- Ultrasmall self-assembling nanocarriers (<30 nm)
- Polymer–drug conjugates (e.g., PGEM)
- Tumor-activated/ tumor-responsive prodrug linkers
- Fixed-dose co-delivery of multiple small-molecule chemotherapies
News & Updates
Completion of GLP toxicology studies with favorable safety profile enabling initiation of first‑in‑human studies for the lead nanomedicine.
Acceptance into the NCL Assay Cascade characterization program for analytical and preclinical testing support.
USPTO issued a composition-of-matter patent strengthening intellectual property protection for the prodrug nanomedicine platform and lead candidate.
NCI STTR award to support additional preclinical studies evaluating duration of action and translational studies for the lead nanomedicine.
Selection to the competitive NCI SBIR Investor Initiatives program to support commercialization and investor engagement.
Nomination recognizing innovation in life sciences for the company’s nanomedicine platform.
Completion of GLP toxicology studies with favorable safety profile enabling initiation of first‑in‑human studies for the lead nanomedicine.
Acceptance into the NCL Assay Cascade characterization program for analytical and preclinical testing support.
USPTO issued a composition-of-matter patent strengthening intellectual property protection for the prodrug nanomedicine platform and lead candidate.
NCI STTR award to support additional preclinical studies evaluating duration of action and translational studies for the lead nanomedicine.
Selection to the competitive NCI SBIR Investor Initiatives program to support commercialization and investor engagement.
Nomination recognizing innovation in life sciences for the company’s nanomedicine platform.